Ascletis raises $107M to advance oral GLP-1 to phase III trials
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Ascletis Pharma’s ASC36 Obesity Move Meets Strong Share Price Momentum
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Sagimet announces positive results for Ascletis’ denifanstat in moderate to severe acne
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
AI-discovered IL-17 inhibitor from Ascletis Pharma shows best-in-class potential
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
China's Ascletis reports 7.7% weight loss for oral GLP-1 contender in US phase 2 study
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Obesity roundup: Structure, Ascletis to move oral contenders to late-stage studies, plus Wave's siRNA
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Ascletis announces phase 2 data for its oral GLP-1 candidate
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Ascletis’ GLP-1RA shows promise with quarterly dosing schedule
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.